Opc,

I recall Al mentioning if there was a large disparity in timing between Type 1 and 2 trial completions the company might consider a Type 1 launch. I used to think this was a major mistake and we needed to take the time and make a splash with both types of diabetes. The type 1 trial seems a bit more streamlined.

I have rethought my opinion on starting with only a Type 1 approval. There has been enough publicity in the diabetes space about Afrezza with the company presenting data at several ADA conferences for doctors to consider off label prescibing. I started my career in the pharmaceutical business and over half of my doctors would consider prescribing drugs I sold for maladies that were not on the label. I know we now live in a different medical climate but with the thousands of patients in the trials and virtually no safety flags, I am sure desperate endo's would consider Afrezza as a prandial insulin prior to Type 2 approval from the FDelay if their patients might benefit from it's use. Especially if the doctors had first hand success with Afrezza on the more difficult Type 1 patients.